Veijo Hukkanen
MDPhD

Clinical instructor
Clinical Lecturer, Institute of Biomedicine (Institute of Biomedicine)
Adjunct Professor, Faculty of Medicine (Faculty of Medicine)

veijo.hukkanen@utu.fi
+358 29 450 4552
Kiinamyllynkatu 10
Turku





Areas of expertise
Virology; Herpesviruses; Gene Therapy; Oncolytic viruses; Oncolytic Immunotherapy; Antivirals

Biography

Thesis work on neuroimmunology and neurovirology 1978-1982

Herpesvirology research 1983-current

Chairperson of the Institute of Microbiology and Pathology (Kliinis-teoreettinen laitos) 2001-2003

Convener and Co-chair of the International Herpesvirus conference IHW2005, Turku, 2005

Professor at the Department of Medical Microbiology, University of Oulu (virology) 2005-2009

Professor at the Department of Virology, University of Turku, 2010-2013



Research

Herpes simplex virus (HSV) is a common pathogen of humans, causing a spectrum of infections ranging from cold sores and genital herpes to the serious neonatal herpes infections and encephalitis. However, HSV is also one of the most important oncolytic viruses (destroying cancer cells) and gene therapy vectors. A characteristic feature of HSV is the latent infection in the nervous system, mainly in sensory ganglia. The latent HSV infection is permanent, although recurrencies can be treated with antiviral drugs. Our project elucidates innate immunity to HSV, and develops means for prevention and treatment of infection and latency. We have a new RNA interference approach using enzymatically produced antiviral siRNA swarms for control of HSV infection, within a joint project with a premier RNA research laboratory in Finland. 

HSV is a promising backbone for gene therapy vectors, due to its neurotropism, its immune evasion abilities, drug sensitivity and numerous other beneficial properties. An oncolytic HSV has gained approval by the FDA and the European Medicines Agency.  Our team has long-term experience in developing HSV vectors. We use the bacterial artificial chromosome (BAC) technology and study the use of these attenuated viruses in gene therapy of central nervous system diseases. We develop oncolytic HSV for treatment of cancer. Our research has produced new HSV vectors, from which therapeutic cytokines and trophic factors are expressed.  We improve delivery and targeting methods for HSV gene therapy. 

We elucidate genetic diversity among HSV strains from natural clinical isolates. We apply NGS sequencing methods suitable for analysis of large DNA viruses, in collaboration with a pioneer laboratory of the field. These studies benefit antiviral development, pathogenesis studies, and virus vector development. We also improve molecular diagnostic methods for the herpes viruses in clinical diseases, having many decades of experience in HSV nucleic acid detection. We collaborate with significant domestic and international research groups. Our project has yielded many doctoral dissertations, in addition to numerous MSc theses and special projects in fields of biomedicine and other biosciences.



Teaching

My interest is in activating teaching of Virology and gene therapy to students of medicine and biomedicine. My teaching is based on scientific research. I have completed the first organized training course in University Pedagogics in the University of Turku, and the first organized training course in Medical Pedagogics in the University of Turku.



Publications
Go to first page Go to previous page 1 of 2 Go to next page Go to last page

Comparison of Herpes Simplex Virus 1 Strains Circulating in Finland Demonstrates the Uncoupling of Whole-Genome Relatedness and Phenotypic Outcomes of Viral Infection (2019)
Journal of Virology
Bowen CD, Paavilainen H, Renner DW, Palomäki J, Lehtinen J, Vuorinen T, Norberg P, Hukkanen V, Szpara ML
(
A1 Journal article – refereed)

Herpes simplex and human papilloma virus coinfections in oral mucosa of men-A 6-year follow-up study (2018)
Journal of Medical Virology
Mäki Johanna, Paavilainen Henrik, Kero Katja, Hukkanen Veijo, Syrjänen Stina
(
A1 Journal article – refereed)

Novel activities of safe-in-human broad-spectrum antiviral agents (2018)
Antiviral Research
Aleksandr Ianevski, Eva Zusinaite, Suvi Kuivanen, Mårten Strand, Hilde Lysvand, Mona Teppor, Laura Kakkola, Henrik Paavilainen, Mira Laajala, Hannimari Kallio-Kokko, Miia Valkonen, Anu Kantele, Kaidi Telling, Irja Lutsar, Pille Letjuka, Natalja Metelitsa, Valentyn Oksenych, Magnar Bjørås, Svein Arne Nordbø, Uga Dumpis, Astra Vitkauskiene, Christina Öhrmalm, Kåre Bondeson, Anders Bergqvist, Tero Aittokallio, Rebecca J. Cox, Magnus Evander, Veijo Hukkanen, Varpu Marjomaki, Ilkka Julkunen, Olli Vapalahti, Tanel Tenson, Andres Merits, Denis Kainov
(
A1 Journal article – refereed)

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses (2018)
Molecular Therapy
Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylösmäki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala, Vincenzo Cerullo
(
A1 Journal article – refereed)

Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins (2017)
Viruses
Daria Bulanova, Aleksandr Ianevski, Andrii Bugai, Yevhen Akimov, Suvi Kuivanen, Henrik Paavilainen, Laura Kakkola, Jatin Nandania, Laura Turunen, Tiina Ohman, Hanna Ala-Hongisto, Hanna M. Pesonen, Marika S. Kuisma, Anni Honkimaa, Emma L. Walton, Valentyn Oksenych, Martina B. Lorey, Dmitry Guschin, Jungmin Shim, Jinhee Kim, Thoa T. Than, So Young Chang, Veijo Hukkanen, Evgeny Kulesskiy, Varpu S. Marjomaki, Ilkka Julkunen, Tuula A. Nyman, Sampsa Matikainen, Jani S. Saarela, Famara Sane, Didier Hober, Gülsah Gabriel, Jef K. De Brabander, Miika Martikainen, Marc P. Windisch, Ji-Young Min, Roberto Bruzzone, Tero Aittokallio, Markus Vähä-Koskela, Olli Vapalahti, Arto Pulk, Vidya Velagapudi, Denis E. Kainov
(
A1 Journal article – refereed)

Chromatin organization regulates viral egress dynamics (2017)
Scientific Reports
Aho V, Myllys M, Ruokolainen V, Hakanen S, Mäntylä E, Virtanen J, Hukkanen V, Kühn T, Timonen J, Mattila K, Larabell CA, Vihinen-Ranta M
(
A1 Journal article – refereed)

Regulation of kynurenine biosynthesis during influenza virus infection (2017)
FEBS Journal
Gaelings L, Söderholm S, Bugai A, Fu Y, Nandania J, Schepens B, Lorey MB, Tynell J, Vande Ginste L, Le Goffic R, Miller MS, Kuisma M, Marjomäki V, De Brabander J, Matikainen S, Nyman T, Bamford D, Saelens X, Julkunen I, Paavilainen H, Hukkanen V, Velagapudi V, Kainov DE
(
A1 Journal article – refereed)

The ERK-1 function is required for HSV-1-mediated G1/S progression in HEP-2 cells and contributes to virus growth (2017)
Scientific Reports
Colao I, Pennisi R, Venuti A, Nygårdas M, Heikkilä O, Hukkanen V, Sciortino MT
(
A1 Journal article – refereed)

Topical treatment of herpes simplex virus infection with enzymatically created siRNA swarm (2017)
Antiviral Therapy
Henrik Paavilainen, Jenni Lehtinen, Alesia Romanovskaya, Michaela Nygårdas, Dennis H Bamford, Minna M Poranen, Veijo Hukkanen
(
A1 Journal article – refereed)

Herpes simplex virus 1 induces egress channels through marginalized host chromatin (2016)
Scientific Reports
Myllys M, Ruokolainen V, Aho V, Smith EA, Hakanen S, Peri P, Salvetti A, Timonen J, Hukkanen V, Larabell CA, Vihinen-Ranta M
(
A1 Journal article – refereed)

HSV-1 Infection Modulates the Radioresponse of a HPV16-positive Head and Neck Cancer Cell Line (2016)
Anticancer Research
Turunen A, Hukkanen V, Kulmala J, Syrjanen S
(
A1 Journal article – refereed)

Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools (2016)
Journal of Medical Virology
Paavilainen H, Lehtinen J, Romanovskaya A, Nygardas M, Bamford DH, Poranen MM, Hukkanen V
(
A1 Journal article – refereed)

Interleukin-27 Inhibits Herpes Simplex Virus Type 1 Infection by Activating STAT1 and 3, Interleukin-6, and Chemokines IP-10 and MIG (2016)
Journal of Interferon and Cytokine Research
Heikkila O, Nygardas M, Paavilainen H, Ryodi E, Hukkanen V
(
A1 Journal article – refereed)

Mikrobit ja Alzheimerin tauti -vähätelläänkö negatiivisia tuloksia (2016)
Lääkärilehti
Hukkanen V, Vuorinen T
(
D1 Article in a trade journal)

Onkolyyttinen geenihoitovirus tulossa osaksi ihomelanooman lääkehoitoa (2016)
Lääkärilehti
Hukkanen Veijo, Vihinen Pia
(
D1 Article in a trade journal)

The γ134.5 Neurovirulence Gene of Herpes Simplex Virus 1 Modifies the Exosome Secretion Profile in Epithelial Cells (2016)
Journal of Virology
Heikkilä Outi, Ryödi Elina, Hukkanen Veijo
(
A1 Journal article – refereed)

An investigation of herpes simplex virus type 1 latency in a novel mouse dorsal root ganglion model suggests a role for ICP34.5 in reactivation (2015)
Journal of General Virology
Mattila RK, Harila K, Kangas SM, Paavilainen H, Heape AM, Mohr IJ, Hukkanen V
(
A1 Journal article – refereed)

Carriage of herpes simplex virus and human papillomavirus in oral mucosa is rare in young women: A long-term prospective follow-up (2015)
Journal of Clinical Virology
Mäki J, Paavilainen H, Grenman S, Syrjänen S, Hukkanen V
(
A1 Journal article – refereed)

Herpes simplex ja Alzheimerin tauti (2015)
Tekniikan maailma
Hukkanen V, Vuorinen T
(
E1 Popularised article, newspaper article)

Innate responses to small interfering RNA pools inhibiting herpes simplex virus infection in astrocytoid and epithelial cells (2015)
Innate Immunity
Henrik Paavilainen, Alesia Romanovskaya, Michaela Nygårdas, Dennis H Bamford, Minna M Poranen, Veijo Hukkanen
(
A1 Journal article – refereed)


Last updated on 2019-15-07 at 02:32